Straits Times Index
3,146.19 -37.42 (-1.18%) Nikkei
38,471.20 -761.60 (-1.94%) Hang Seng
16,234.32 -366.14 (-2.21%) FTSE 100
7,851.71 -113.82 (-1.43%) Bitcoin USD
63,487.18 -2,906.21 (-4.38%) CMC Crypto 200
885.54 0.00 (0.00%)
Biomea Fusion, Inc. (BMEA)
After hours:
| Previous close | 12.98 |
| Open | 12.88 |
| Bid | 12.49 x 500 |
| Ask | 12.58 x 100 |
| Day's range | 12.11 - 13.37 |
| 52-week range | 8.12 - 43.69 |
| Volume | |
| Avg. volume | 1,022,767 |
| Market cap | 448.976M |
| Beta (5Y monthly) | -0.54 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.44 |
| Earnings date | 01 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 54.43 |
GlobeNewswireBiomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases, today announced that on April 1, 2024, the compensation committee of Biomea’s board of directors granted two new employees non-qualified stock options to purchase an aggregate of 6,500 shares
- GlobeNewswire
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes The first two type 1 diabetes patients enrolled in COVALENT-112 both demonstrated early signs of clinical activity with improved measures of beta-cell function after initial treatment with BMF-219BMF-219 has been well tolerated by both patientsOpen label portion of Phase II COVALENT-112 study readout of 40 patients with type 1 diabetes dosed for 12 weeks
- GlobeNewswire
Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
In 2023, reported Phase 2 data (COVALENT-111) in type 2 diabetes patients supporting the disease-modifying potential of BMF-219 to address a root cause of diabetes: a loss of healthy, insulin-producing beta cells. After just a 4-week treatment period in type 2 diabetes patients, who had previously failed standard of care (HbA1c > 7.0% and < 10%), BMF-219 demonstrated continued glycemic control at 26 weeks, or five months, after cessation of dosing.Enrollment underway in COVALENT-111 expansion co
